HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xin Li Selected Research

Lymphoma (Lymphomas)

1/2022Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
1/2022CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
1/2022Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
10/2021Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial.
3/2021Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
1/2021Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study.
12/2020Corrigendum to "SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type" [Leukemia Res. 96 (2020) 106422].
1/2020Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
1/2020SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
1/2020miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xin Li Research Topics

Disease

827Neoplasms (Cancer)
10/2022 - 03/2002
172Infections
10/2022 - 01/2004
166Inflammation (Inflammations)
09/2022 - 12/2005
137Neoplasm Metastasis (Metastasis)
10/2022 - 05/2004
103Breast Neoplasms (Breast Cancer)
08/2022 - 12/2006
92Hepatocellular Carcinoma (Hepatoma)
07/2022 - 03/2003
78Carcinogenesis
07/2022 - 02/2003
68Hypoxia (Hypoxemia)
07/2022 - 08/2002
67Prostatic Neoplasms (Prostate Cancer)
12/2021 - 02/2003
56Lung Neoplasms (Lung Cancer)
08/2022 - 07/2009
50COVID-19
11/2022 - 01/2020
50Fibrosis (Cirrhosis)
10/2022 - 11/2003
49Carcinoma (Carcinomatosis)
01/2022 - 06/2002
46Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2022 - 09/2005
46Insulin Resistance
05/2022 - 12/2005
44Colorectal Neoplasms (Colorectal Cancer)
09/2022 - 11/2003
43Stroke (Strokes)
08/2022 - 08/2009
42Pain (Aches)
04/2022 - 01/2007
41Alzheimer Disease (Alzheimer's Disease)
06/2022 - 01/2010
41Type 2 Diabetes Mellitus (MODY)
05/2022 - 07/2011
40Body Weight (Weight, Body)
04/2022 - 12/2002
37Multiple Myeloma
01/2022 - 12/2006
35Adenocarcinoma
01/2022 - 10/2006
35Melanoma (Melanoma, Malignant)
01/2022 - 06/2006
34Sepsis (Septicemia)
03/2022 - 09/2010
34Pancreatic Neoplasms (Pancreatic Cancer)
08/2021 - 01/2013
33Parkinson Disease (Parkinson's Disease)
07/2022 - 07/2008
33Ischemia
01/2022 - 10/2004
32Obesity
08/2022 - 10/2006
32Nasopharyngeal Carcinoma
01/2022 - 12/2003
31Uterine Cervical Neoplasms (Cancer of the Cervix)
07/2022 - 12/2004
31Ovarian Neoplasms (Ovarian Cancer)
07/2022 - 08/2008
31Glioma (Gliomas)
01/2022 - 04/2009
30Cognitive Dysfunction
06/2022 - 02/2013
30Psoriasis (Pustulosis Palmaris et Plantaris)
04/2022 - 01/2012
30Lymphoma (Lymphomas)
01/2022 - 02/2012
30Leukemia
01/2022 - 10/2007
29Cardiovascular Diseases (Cardiovascular Disease)
06/2022 - 04/2005
29Wounds and Injuries (Trauma)
03/2022 - 04/2006
29Osteosarcoma (Osteogenic Sarcoma)
01/2022 - 02/2007
29Necrosis
01/2022 - 06/2003
28Hypertension (High Blood Pressure)
10/2022 - 12/2011
28Ischemic Stroke
08/2022 - 05/2010
27Hemorrhage
12/2022 - 06/2003
27Myocardial Infarction
01/2022 - 07/2008
26Infarction (Infarctions)
08/2022 - 05/2010
24Stomach Neoplasms (Stomach Cancer)
07/2022 - 01/2009
23Liver Neoplasms (Liver Cancer)
01/2022 - 03/2004
22Adenocarcinoma of Lung
06/2022 - 11/2012
22Hyperplasia
01/2022 - 01/2005
22Reperfusion Injury
01/2021 - 05/2009
21Hyperalgesia
06/2022 - 04/2008
21Mitochondrial Diseases (Mitochondrial Disease)
04/2022 - 07/2008

Drug/Important Bio-Agent (IBA)

319Proteins (Proteins, Gene)FDA Link
10/2022 - 02/2003
160Biomarkers (Surrogate Marker)IBA
08/2022 - 10/2006
155Pharmaceutical PreparationsIBA
08/2022 - 08/2002
124MicroRNAs (MicroRNA)IBA
07/2022 - 07/2007
101Messenger RNA (mRNA)IBA
06/2022 - 02/2003
97Biological ProductsIBA
07/2022 - 12/2006
86CytokinesIBA
07/2022 - 02/2004
64Glucose (Dextrose)FDA LinkGeneric
08/2022 - 12/2005
51Long Noncoding RNAIBA
05/2022 - 09/2016
50LipidsIBA
09/2022 - 04/2005
47RNA (Ribonucleic Acid)IBA
11/2022 - 11/2003
42Therapeutic UsesIBA
09/2022 - 03/2005
42EnzymesIBA
07/2022 - 04/2004
40DNA (Deoxyribonucleic Acid)IBA
01/2022 - 11/2003
36Peptides (Polypeptides)IBA
05/2022 - 02/2007
35Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2022 - 11/2003
35Cisplatin (Platino)FDA LinkGeneric
06/2022 - 04/2004
35LigandsIBA
01/2022 - 12/2004
34Anti-Bacterial Agents (Antibiotics)IBA
05/2022 - 01/2009
33AntigensIBA
10/2022 - 05/2005
33Small Interfering RNA (siRNA)IBA
07/2022 - 08/2008
32Insulin (Novolin)FDA Link
01/2022 - 12/2005
31Interleukin-6 (Interleukin 6)IBA
01/2022 - 12/2005
30Doxorubicin (Adriamycin)FDA LinkGeneric
01/2022 - 08/2012
29VaccinesIBA
10/2022 - 06/2002
29Indicators and Reagents (Reagents)IBA
05/2022 - 03/2005
29Reactive Oxygen Species (Oxygen Radicals)IBA
04/2022 - 04/2010
29Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2022 - 06/2006
29CateninsIBA
01/2021 - 01/2010
26LipopolysaccharidesIBA
06/2022 - 02/2009
25AntibodiesIBA
09/2022 - 08/2011
24Adenosine Triphosphate (ATP)IBA
06/2022 - 11/2004
24AntioxidantsIBA
01/2022 - 04/2004
22CholesterolIBA
11/2022 - 12/2005
22AcidsIBA
08/2022 - 06/2009
22Antiviral Agents (Antivirals)IBA
05/2022 - 05/2009
22Transcription Factors (Transcription Factor)IBA
01/2022 - 07/2004
21Contrast MediaIBA
08/2022 - 11/2011

Therapy/Procedure

389Therapeutics
12/2022 - 09/2002
128Drug Therapy (Chemotherapy)
08/2022 - 06/2002
39Radiotherapy
06/2022 - 03/2010
38Immunotherapy
01/2022 - 06/2006
27Chinese Traditional Medicine (Traditional Chinese Medicine)
07/2022 - 04/2005
27Aftercare (After-Treatment)
02/2022 - 01/2004
26Stents
10/2022 - 05/2010
23Transplantation
01/2022 - 01/2007
21Lasers (Laser)
09/2022 - 01/2011